Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 9/20 | 0.59 |
| ▸ | MME | P08473 | 7/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.59 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550703 | 1.00 | FOLH1 (0.61) | FOLH1ACEMMEACE2NAALAD2 | |
| SCHEMBL30587429 | 0.88 | ACE (0.59) | FOLH1ACEMMEACE2GRIA1 | |
| SCHEMBL18329325 | 0.87 | FOLH1 (0.49) | FOLH1ACEMMEACE2NAALAD2 | |
| SCHEMBL7192956 | 0.87 | FOLH1 (0.49) | FOLH1ACEMMEACE2NAALAD2 | |
| SCHEMBL244885 | 0.87 | NPSR1 (0.69) | ACEMMEACE2NAALAD2CPA1 | |
| SCHEMBL12863002 | 0.87 | NPSR1 (0.69) | ACEMMEACE2NAALAD2CPA1 | |
| SCHEMBL17468460 | 0.87 | NPSR1 (0.69) | ACEMMEACE2NAALAD2CPA1 | |
| SCHEMBL30587426 | 0.86 | ACE (0.58) | FOLH1ACEMMEACE2GRIA1 | |
| SCHEMBL30000049 | 0.86 | ACE (0.58) | FOLH1ACEMMEACE2CPA1 | |
| SCHEMBL7470129 | 0.86 | ACE (0.58) | FOLH1ACEMMEACE2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | claimed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | claimed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | claimed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | claimed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | claimed |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2022-09-20 | — | — | US | disclosed |
| CN-108101958-B | Refining method of glycyl-L-tyrosine | 湖北泓肽生物科技有限公司 | 2020-06-02 | — | — | CN | disclosed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-108101958-A | A kind of process for purification of glycyl-L-tyrosine | 湖北泓肽生物科技有限公司 | 2018-06-01 | — | — | CN | disclosed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | disclosed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | PAM, UACA, FLT1 | FOLH1 3470/4885ACE 3987/4885MME 4177/4885 |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | UACA, PAM, JAK3 | FOLH1 2813/4885ACE 3756/4885MME 4232/4885 |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | PAM, UACA, FLT1 | FOLH1 3470/4885ACE 3987/4885MME 4177/4885 |
| US-20110028509-A1 | Sulfonamides | CXCR3, CXCR2, CXCR1 | FOLH1 2304/4885ACE 2448/4885MME 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.